Myl7 has been shown to inhibit cardiac hypertrophy (Sun et al., 2021), whereas Wif1 impacts hypertrophy through inhibition of the Wnt/β-catenin pathway (Lu et al., 2013). Here, WIF1 is linked to cardiac hypertrophy.